Results 51 to 60 of about 4,766 (189)

Development and Validation of a Simple and Robust Bioanalytical Method for Simultaneous Quantification of Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Human Plasma Using LC–MS/MS and Its Application in a Pharmacokinetic Study

SEPARATION SCIENCE PLUS, Volume 9, Issue 4, April 2026.
ABSTRACT A simple, sensitive, and selective LC–MS/MS method has been developed and validated, in accordance with ICH M10 guidelines, for the simultaneous quantification of Bictegravir (BTV), Emtricitabine (ECB), and Tenofovir alafenamide (TAM) in human plasma.
Boosi Ravi Kumar, Muvvala Venkatanarayana, Shiva Kumar Koppula, Valluru Rajani Kumar   +3 more
wiley   +1 more source

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

, 2008
HIV-1 integrase (IN) is the molecular target of the newly approved anti-AIDS drug raltegravir (MK-0518, Isentress) while elvitegravir (GS-9137, JTK-303) is in clinical trials.
Marchand C, Mott BT, MARINELLO, JESSICA, Pommier Y., Bain A, Thomas CJ   +5 more
core   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, Volume 27, Issue 4, Page 572-584, April 2026.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Pharmacokinetic parameters of elvitegravir in U1 cells.

, 2017
AUCtot, area under the plasma concentration-time curve from time 0 to 24 hours; Cmax, measured maximum plasma concentration; Tmax, time to reach peak concentration. *p#ptot and Cmax, and as median (range) for Tmax.
Pradeep B. Lukka (3775327), Santosh Kumar (106550), Bernd Meibohm (110267), Narasimha M. Midde (309014), Namita Sinha (724836)   +4 more
core   +1 more source

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages

Biochemistry and Biophysics Reports, 2017
Purpose: Monocytes serve as sanctuary sites for HIV-1 from which virus is difficult to be eliminated. Therefore, an effective viral suppression in monocytes is critical for effective antiretroviral therapy (ART).
Yuqing Gong, Pallabita Chowdhury, Narasimha M. Midde, Mohammad A. Rahman, Murali M. Yallapu, Santosh Kumar   +5 more
doaj   +1 more source

Combination of a UPO‐Based Epoxidation With a Subsequent Ring‐Opening Reaction for the Synthesis of Amino Alcohols

ChemBioChem, Volume 27, Issue 5, 13 March 2026.
The synthesis of aromatic amino alcohols via a combination of an unspecific peroxygenase‐catalysed reaction, oxyfunctionalization, and addition of selected nucleophiles and electrophiles in a highly atom‐efficient manner was investigated. This study presents the design to aim for an atom‐efficient chemo‐enzymatic synthesis route towards aromatic amino ...
Simon Last, Niklas Dietz, Martin J. Weissenborn, Jan von Langermann   +3 more
wiley   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients

, 2017
[Objectives] To evaluate if there are significant drug–drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously.[Methods] The study population consisted of three ...
Lopez-Cortes, Luis F, Benmarzouk-Hidalgo, Omar J, Fernández-Magdaleno, Tamara, BenMarzouk-Hidalgo, O. J., Llaves, Silvia, Espinosa, Nuria, Viciana, Pompeyo, López-Cortés, Luis F., Gutierrez-Valencia, Alicia, Gutiérrez Valencia, Alicia   +9 more
core   +1 more source

Multiple choices for HIV therapy with integrase strand transfer inhibitors

Retrovirology, 2012
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several
Raffi Francois, Wainberg Mark A
doaj   +1 more source